thyroid cancer
Advertisement
FDA Approves Retevmo® for RET-Mutated Lung, Thyroid Cancers
Kerri FitzgeraldNon-Small Cell Lung Cancer | September 20, 2023
The U.S. Food and Drug Administration approved Retevmo® (selpercatinib) for three types of RET-mutated cancer: adults ...
Read More
Advertisement
Advertisement
Advertisement
Latest News

HARMONi-2 Interim Analysis: Ivonescimab Shows PFS Improvements Over Pembrolizumab in NSCLC

March 7, 2025

Stephen Liu, MD, on Key Debates in NSCLC

March 7, 2025

How Frequent Is Suture-Line Recurrence After Surgery for Early-Stage NSCLC?

March 5, 2025

CROWN 5-Year Subgroup Analysis Shows PFS Is Consistent With Overall Patient Population

March 5, 2025

Can Systematic Immune Inflammation Predict Survival in Patients Receiving Immune Checkpoint Inhibitors for NSCLC?

March 5, 2025

LUPER Study Evaluates Lurbinectedin Plus Pembrolizumab in Relapsed SCLC

March 5, 2025

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Contribute

    Our Network

    MashupMD

    Blood Cancers Today

    Cancer Nursing Today

    GU Oncology Now

    Urban Health Today

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |